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Abstract
Introduction:  Clostridium  difﬁcile  (C.  difﬁcile)  is  a  Gram-positive  bacillus  that  is  a  common
cause of  diarrhea  in  the  hospital  environment,  with  a  documented  incidence  of  up  to  10%.
There are  different  methods  to  detect  it,  but  a  widely  used  test  in  our  environment  is  the
immunoassay  for  toxins  A  and  B.
Aims:  The  aim  of  our  study  was  to  1)  estimate  the  positive  predictive  value  of  the  immunoassay
for the  detection  of  the  C.  difﬁcile  toxins  A  and  B,  2)  to  establish  the  incidence  of  C.  difﬁcile
associated  diarrhea  in  the  hospital,  and  3)  to  know  the  most  common  associated  factors.
Methods: A  diagnostic  test  accuracy  study  was  conducted  within  the  time  frame  of  January
2010 to  August  2013  at  the  Hospital  Christus  Muguerza®  Alta  Especialidad  on  patients  with
symptoms  suggestive  of  C.  difﬁcile-associated  diarrhea  that  had  a  positive  immunoassay  test
and conﬁrmation  of  C.  difﬁcile  through  colon  biopsy  and  stool  culture.
Results:  The  immunoassay  for  toxins  A  and  B  was  performed  in  360  patients.  Fifty-ﬁve  of  the
cases had  positive  results,  35  of  which  showed  the  presence  of  C.  difﬁcile. Incidence  was  10.2%
and the  positive  predictive  value  of  the  test  for  C.  difﬁcile  toxins  A  and  B  was  0.64  (95%  CI,
0.51-0.76).  Previous  antibiotic  therapy  (n  =  29)  and  proton  pump  inhibitor  use  (n  =  19)  were  the
most common  associated  factors.
Conclusions:  C.  difﬁcile  incidence  in  our  environment  is  similar  to  that  found  in  the  literature
reviewed,  but  the  positive  predictive  value  of  the  test  for  toxin  A  and  B  detection  was  low.
© 2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Published  by  Masson  Doyma  Me´xico  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
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Valor  predictivo  positivo  de  la  prueba  de  inmunoanálisis  para  detección  de  toxina  A
y  B  de  Clostridium  difﬁcile  en  un  hospital  privado
Resumen
Introducción:  Clostridium  difﬁcile  (C.  difﬁcile)  es  un  bacilo  grampositivo,  causa  común  de
diarrea en  el  medio  hospitalario;  siendo  la  incidencia  documentada  hasta  un  10%.  Hay  distin-
tos medios  para  su  detección  sin  embargo  en  nuestro  medio,  una  prueba  muy  utilizada  es  el
inmunoanálisis  de  toxinas  A  y  B.
Objetivos:  1)  Estimar  el  valor  predictivo  positivo  de  la  prueba  de  inmunoanálisis  para  detección
de toxinas  A  y  B  de  C.  difﬁcile;  2)  establecer  la  incidencia  de  diarrea  por  C.  difﬁcile  en  el
hospital, y  3)  conocer  los  factores  asociados  más  comunes.
Métodos:  Estudio  de  prueba  diagnóstica.  Se  incluyó  a  los  pacientes  con  cuadro  indicativo  de
diarrea por  C.  difﬁcile  de  enero  del  2010  a  agosto  del  2013,  en  el  Hospital  Christus  Muguerza
Alta Especialidad  y  con  prueba  de  inmunoanálisis  positiva,  y  que  se  comprobó  por  biopsia  de
colon y  cultivo  de  muestra  fecal  para  determinación  de  C.  difﬁcile.
Resultados:  Se  analizó  a  360  pacientes  a  los  que  se  le  solicitaron  toxinas  A  y  B,  de  los  cuales
55 casos  resultaron  positivos;  en  35  se  demostró  la  presencia  de  C.  difﬁcile. La  incidencia  fue
del 10.2%  y  el  valor  predictivo  positivo  (VPP)  de  la  prueba  de  toxinas  A  y  B  de  C.  difﬁcile  fue  de
0.64 (intervalo  de  conﬁanza  del  95%,  0.51-0.76).  Se  encontró  que  el  uso  de  antibioticoterapia
previa (n  =  29)  y  de  inhibidores  de  bomba  de  protones  (n  =  19)  fue  el  factor  asociado  más  común.
Conclusiones:  La  incidencia  de  C.  difﬁcile  en  nuestro  medio  es  similar  a  la  literatura  revisada;
sin embargo,  el  VPP  de  la  prueba  de  detección  de  toxinas  A  y  B  fue  bajo.
© 2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Alta  Especialidad  above  the  age  of  18  years  that  had  clinicalIntroduction
Clostridium  difﬁcile  (C.  difﬁcile)  is  the  most  common  infec-
tious  cause  of  diarrhea  in  hospitalized  patients  and  is
associated  with  substantial  mortality  and  elevated  economic
cost.1 In  the  United  States,  1  out  of  every  100  hospital-
ized  patients  develops  diarrhea  due  to  C.  difﬁcile,  whereas
community  incidence  is  1  out  of  every  100,000.2
C.  difﬁcile  is  a  Gram-positive  anaerobic  toxigenic  spore-
forming  bacillus  that  has  a  wide  range  of  manifestations.  The
result  of  colonization  ranges  from  being  an  asymptomatic
carrier  to  the  development  of  pseudomembranous  colitis.3
Inoculation  occurs  in  5-15%  of  healthy  persons  and  trans-
mission  is  usually  through  the  same  healthcare  workers  that
become  contaminated  by  other  infected  patients.  In  the
United  States,  the  reported  incidence  is  1-2%  in  hospital-
ized  patients.4 Some  of  the  main  causes  that  predispose
to  infection  are:  antibiotic  use,  among  which  clindamycin,
cephalosporins,  amoxicillin,  and  ﬂuoroquinolones  are  the
most  related;  age  above  65  years;  prolonged  hospitalization;
and  the  use  of  proton  pump  inhibitors.5--8 Mortality  associ-
ated  with  C.  difﬁcile-caused  diarrhea  is  high,  reaching  65%
in  the  untreated  elderly.9,10
The  deﬁnitive  diagnosis  is  made  when  C.  difﬁcile  cyto-
toxins  are  demonstrated  in  stool  samples.  The  reference
method  is  the  toxin  B  cytotoxicity  test  in  cell  cultures  (gold
standard)  that  is  capable  of  detecting  a  small  quantity  of
toxin  (10  pg)  in  stool  with  elevated  sensitivity  (94-100%)
and  speciﬁcity  (99%).11 The  main  disadvantages  are  that
cell  cultures  are  not  available  in  all  laboratories,  together
with  the  incubation  period  of  48-72  hours.  Given  its  speed
s
o
f2-6  h)  and  lower  cost,  the  most  widely  used  method  is  the
mmunoassay  for  Toxins  A  and  B,  which  has  71-94%  sensi-
ivity  and  92-98%  speciﬁcity.  The  latex  agglutination  test
as  insufﬁcient  sensitivity  at  approximately  48  to  59%.12,13
nother  utilized  method  is  that  of  the  nucleic  acid  ampli-
cation  tests,  such  as  the  polymerase  chain  reaction  (PCR)
est.  It  has  100%  sensitivity  and  96%  speciﬁcity,  but  it  is  a
omplex  and  expensive  technique  and  detects  asymptomatic
arriers.11
The  aims  of  the  present  study  were  to  determine  the
ositive  predictive  value  of  the  immunoassay  used  in  our
ospital  for  the  detection  of  the  C.  difﬁcile  A  and  B  toxins,
o  establish  the  incidence  of  C.  difﬁcile-associated  diarrhea,
nd  to  know  the  most  common  associated  factors.
aterials and methods
 single-center,  observational,  descriptive,  retrolective,
iagnostic  test  accuracy  study  was  conducted.  The  incidence
f  C.  difﬁcile-associated  diarrhea  within  the  hospital  and
he  predictive  value  of  the  immunoassay  for  the  detection  of
.  difﬁcile  toxins  A  and  B  were  evaluated  and  compared  with
he  anatomopathologic  result  and  culture.  In  addition,  the
ost  common  associated  risk  factors  in  the  patients  were
ocumented.  The  information  was  obtained  from  the  case
ecord  registry  of  the  Biostatistics  department.
All  the  patients  seen  at  the  Hospital  Christus  Muguerza®uspicion  for  C.  difﬁcile-associated  diarrhea  upon  admission
r  during  their  hospital  stay  and  in  whom  the  immunoassay
or  the  A  and  B toxins  was  ordered  were  included  in  the
1 S.E.  Pérez-Topete  et  al.
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Table  1  Epidemiologic  characteristics  of  the  population.
Characteristics
n  (%)  mean  ±  SD
Sex
M  17  (31)
W  38  (69)
Age  (years)  53.6  (±  20.8)
Hospitalization
Intensive  care  unit  6  (11)
General  ward  49  (89)
Days  of  hospital  stay  7.3  (±3.2)
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tudy.  In  the  patients  that  had  a  positive  test,  their  case
ecords  stated  that  the  presence  of  C.  difﬁcile  was  con-
rmed  through  colon  biopsy  and  colonoscopy  culture  within
he  time  frame  of  January  2010  to  August  2013.
Patients  under  the  age  of  18  years,  that  had  positive  titers
or  the  C.  difﬁcile  toxins  A  and  B  test  in  the  previous  8
eeks,  or  whose  case  record  information  was  insufﬁcient,
ere  excluded  from  the  study.
The  qualitative  enzyme  immunoassay  Premier®Toxins
&B  was  the  test  used  at  the  Hospital  Christus  Muguerza®
lta  Especialidad  for  the  detection  of  C.  difﬁcile  A  and  B
oxins.  This  immunoassay  utilizes  stool  samples  placed  in
icrowells  that  are  sealed  with  monoclonal  and  polyclonal
ntibodies  speciﬁc  for  the  toxins,  which  if  present  in  the
amples,  form  antibody-antigen  complexes,  converting  the
ubstrate/chromogen  into  a  colored  product  that  is  com-
ared  with  a  negative  and  positive  control  that  is  a  deﬁnite
ellow.  It  detects  levels  >  1.4  ng/ml  of  toxin  A  and  >  2.4
g/ml  of  toxin  B.
tatistical analysis
he  quantitative  variables  are  expressed  as  means  ±
tandard  deviation  and  the  categorical  variables  are
xpressed  as  percentages.  The  incidence  of  C.  difﬁcile-
ssociated  diarrhea  was  calculated  and  the  positive
redictive  value  of  the  test  was  determined  with  a  2  x  2
able  with  95%  conﬁdence  intervals  (CI)  using  the  Wald  for-
ula.  The  Excel  database  sheet  and  Medcalc  software  were
mployed  for  the  result  compilation.
esults
 total  of  360  patients  were  analyzed  (ﬁg.  1)  in  whom  the
mmunoassay  for  detecting  the  C.  difﬁcile  toxins  A  and  B
as  carried  out.  Of  those  patients,  55  cases  had  positive
est  results.  The  following  variables  were  analyzed:  age,
ex,  associated  risk  factors,  days  of  hospital  stay,  stay  in
360 patients with
test for C. difficile
toxins A and B
55 patients with
positive test for
C. difficile
toxins A and B
35 patients were
positive for C. difficile
in biopsy and culture
20 patients were
negative for  C. difficile
in biopsy and culture
305 patients with
negative test  for
C. difficile toxins
A and B
 
Figure  1  Study  ﬂow  chart.
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PM: Men; n: number of the population, SD: Standard deviation;
W:  Women.
he  intensive  care  unit  (ICU),  anatomopathologic  result,  and
reatment.
The  mean  age  of  the  patients  with  positive  immunoassay
as  53.6  ±  20.8  years  (Table  1)  and  the  most  frequent  age
as  that  of  50  to  65  years.  In  relation  to  sex  distribution,  38
f  the  patients  were  women  (69%)  and  17  were  men  (31%).
Of  the  positive  sample  total,  6 patients  (11%)  were  in  the
CU,  one  of  whom  died  while  there,  and  49  patients  were  in
he  general  wards  (89%).
The  patients  diagnosed  with  C.  difﬁcile-associated  diar-
hea  had  a  mean  hospital  stay  of  7.3  ±  3.2  days.
Colonoscopy  was  performed  on  the  55  patients,  all  of
hom  had  suggestive  data  that  was  correlated  with  C.  difﬁ-
ile  through  biopsy  and  culture  in  35  of  those  patients  (64%),
hereas  no  correlation  was  found  in  20  of  the  patients  (36%).
Of  the  20  patients  with  negative  results,  nonspeciﬁc
hronic  and  acute  inﬂammation  was  documented  in  only  10
f  them,  Crohn’s  disease  in  3,  ulcerative  colitis  in  3,  nor-
al  histopathologic  studies  in  3,  and  infectious  colitis  due
o  Cryptosporidium  in  one  patient.
Among  the  risk  factors  associated  with  infection  due  to
.  difﬁcile  (ﬁg.  2)  were  the  use  of  proton  pump  inhibitors
nd  having  taken  an  antibiotic,  of  which  ciproﬂoxacin  was
he  most  related  (ﬁg.  3).
Of  the  55  patients  with  a  positive  test  for  C.  dif-
cile  toxins  A  and  B,  28  of  them  (51%)  were  treated
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igure  2  Risk  factors  associated  with  infection  due  to
lostridium  difﬁcile.
PI:  Proton  pump  inhibitor.
Positive  predictive  value  for  Clostridium  difﬁcile  toxin  A  and  B  d
Ciprofloxacin
Not specified
Trimethoprim/
sulfamethoxazole
Ampicillin
Ceftriaxone
Clindamycin
Dicloxacillin
Amikacin
8.28%
8.28%4.14%
3.10%
3.10%
1.4%
1.3%
1.3% c
d
C
m
C
a
b
d
i
t
p
a
a
w
r
w
c
r
v
g
r
l
c
m
s
C
C
i
f
o
f
c
t
e
a
t
s
E
P
t
f
D
d
R
dFigure  3  Previous  antibiotic  therapy  associated  with  Clostrid-
ium difﬁcile  infection.
with  metronidazole,  13  (24%)  with  vancomycin,  and  14  (25%)
required  combination  therapy  with  metronidazole  and  van-
comycin.
The  incidence  of  C.  difﬁcile-associated  diarrhea
detected  at  the  Hospital  Christus  Muguerza®  Alta  Espe-
cialidad  through  the  Toxin  A  and  B  immunoassay  was
10.2%  during  a  3-year  period  and  the  positive  predictive
value  of  the  immunoassay  utilized,  in  relation  to  the
anatomopathologic  diagnosis,  was  0.64  (95%  CI,  0.51-0.76).
Discussion
C.  difﬁcile  infection  is  deﬁnitely  a  common  etiologic  agent
of  intrahospital  diarrhea  in  our  environment  and  its  inci-
dence  is  similar  to  that  reported  in  the  literature.1
For  many  years,  toxin  A  and  B  detection  in  stools  through
cellular  cytotoxicity  was  considered  the  gold  standard  for
the  diagnosis  of  C.  difﬁcile  infection.  Recent  studies  have
shown  that  toxin  culture  has  a  greater  diagnostic  potential
and  therefore  should  be  the  new  gold  standard.  However,
both  tests  are  slow,  laborious,  and  require  trained  person-
nel.  For  these  reasons,  the  enzyme  immunoassays  for  toxin
detection  are  the  most  widely  used  for  the  diagnosis  of  C.
difﬁcile  infection.14
Novak  et  al.15 compared  the  different  tests  employed  for
the  diagnosis  of  C.  difﬁcile  infection  and  found  a  positive
predictive  value  of  0.68  for  the  toxin  A  and  B  test,  which
was  similar  to  that  found  in  our  study  (0.64).  In  other  analy-
ses,  such  as  those  by  Eastwood  et  al.16 and  Planche  et  al.17
that  evaluated  the  sensitivity  and  speciﬁcity  of  the  tests  for
the  detection  of  the  C.  difﬁcile  toxins  A  and  B  in  stool  sam-
ples,  values  of  83  and  95%,  respectively,  a  positive  predictive
value  of  70%,  and  a  negative  predictive  value  of  96%  were
reported.
Other  potential  diagnostic  options  that  have  been
described  in  the  literature  are  the  detection  of  glutamate
dehydrogenase  glutamate,  PCR,  and  the  nucleic  acid  ampli-
ﬁcation  test  (NAAT).14
Glutamate  dehydrogenase  detection  can  be  used  as  a
screening  test  because  it  has  close  to  100%  sensitivity,  but
it  has  the  disadvantage  of  having  low  speciﬁcity.18 PCR  and
NAAT  have  excellent  sensitivity  and  speciﬁcity,  almost  90%,
which  is  why  they  have  become  the  diagnostic  method  of
F
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hoice  in  some  centers.  However,  both  tests  are  costly  and
o  not  detect  toxin  production  and  thus  cannot  distinguish
.  difﬁcile  infection  from  asymptomatic  carriage.19,20
Current  American  and  European  guidelines  have  recom-
ended  a two-step  algorithm  for  the  laboratory  diagnosis  of
.  difﬁcile  infection  that  uses  a  highly  sensitive  test,  such
s  that  which  detects  glutamate  dehydrogenase,  followed
y  a  highly  speciﬁc  one,  such  as  immunoassay  toxin  A  and  B
etection.18 Some  have  even  proposed  a  third  step  of  order-
ng  toxin  culture  for  those  patients  negative  for  toxins,  but
hat  have  strongly  suspicious  symptoms.21
The  main  documented  associated  risk  factors  were  the
revious  use  of  antibiotics  and  proton  pump  inhibitors,
s  reported  in  the  study  by  Camacho  et  al.7 Among  the
ntibiotics,  quinolone  use  was  the  most  related  to  infection
ith  respect  to  antimicrobials,  according  to  the  literature
eviewed.5,10
In  regard  to  therapeutic  management,  metronidazole
as  the  main  drug  used,  in  addition  to  vancomycin  or  the
ombination  of  the  two,  concurring  with  the  management
eported  in  the  literature.4,5 Due  to  the  emergence  of  hyper-
irulent  strains,  disease  severity,  increased  sporulation,  and
reater  antimicrobial  resistance,  the  therapeutic  options  for
ecurrent  or  treatment  refractory  C.  difﬁcile  infection  are
imited.  Rifaximin,  ﬁdaxomicin,  nitazoxanide,  and  tigecy-
line  have  been  used  as  alternatives  in  those  cases.  Fecal
icrobiota  transplantation  is  also  another  therapeutic  mea-
ure  for  recurrence.22
onclusions
.  difﬁcile  incidence  in  our  environment  was  similar  to  that
n  the  literature  reviewed,  but  the  positive  predictive  value
or  the  test  was  low.  Proton  pump  inhibitor  use  and  previ-
us  antibiotic  therapy  were  the  most  highly  associated  risk
actors.
The  determination  of  C.  difﬁcile  toxins  A  and  B  should
ontinue  to  be  an  important  diagnostic  test  for  the  oppor-
une  detection  of  C.  difﬁcile-associated  infection  in  our
nvironment  because  it  has  a  low  cost,  is  fast,  available,
nd  easy  to  perform.  This  is  especially  true  for  those  cen-
ers  that  have  no  other  methods  for  conﬁrming  symptoms
uggestive  of  this  entity.
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